Myopia Clinical Trial
Official title:
Comparison Between TPRK Versus AAPRK in Correction of Myopia and Myopic Astigmatism
PURPOSE: The aim of the study is to compare visual acuity means, refractive results, safety,
and efficacy of TPRK with AAPRK as primary outcomes and surgical time, pain scores, haze
levels, and healing time as secondary outcomes.
SETTING: Security Forces Hospital, Ophthalmology Department, Riyadh, Kingdom of Saudi Arabia.
DESIGN: Prospective, consecutive, nonrandomized case-control comparative study.
. METHODS: A total of 200 eyes of 100 patients were included. One hundred eyes underwent TPRK
in the right eye (study group) and 100 eyes underwent AAPRK in the left eye (control group).
Ablations performed with the Schwind Amaris, 750S. Clinical outcomes were compared Paired
student's t-tests and Mann-Whitney tests were used for statistical analysis.
Introduction Previous studies document that, although Laser in situ keratomileusis (LASIK) is
the most worldwide performed refractive procedure, surface ablation may be safer to avoid
flap complications, corneal weakening, and a higher risk of iatrogenic keratectasia
associated with LASIK and thus the era of surface ablation emerged as an alternative (1).
Photorefractive keratectomy (PRK) is one of the surface ablation procedures and performed
after corneal epithelial debridement accompanied by post-operative pain, discomfort, and high
grade of corneal haze, all of which limit its popularity (2). The traditional method for
corneal epithelium removal before excimer LASER was manual scraping, which was later enhanced
by using an alcohol solution 20% or brush (3). In 2003, Camellin introduced a new
alcohol-assisted technique called laser-assisted subepithelial keratectomy (LASEK) that
allowed the epithelium to be preserved as a flap and applied back to the stromal corneal bed
after laser treatment (4). Also in 2003, Pallikaris invented epithelial laser in situ
keratomileusis (Epi-LASIK) which is another method that uses the epithelial flap and
performed with a microkeratome (called epi-keratome) with a blunt oscillating blade. After
trans-epithelial photorefractive keratectomy (TPRK) was introduced, where removal of the
epithelium is done by phototherapeutic ablation followed by refractive ablation of the
corneal stroma. Several studies emerged and advocated many techniques for epithelial removal
, but this 2-step technique was not worldwide used due to the prolonged surgery time with the
older generation of lasers, corneal dehydration, increased post-operative pain, and a
deficiency of adjusted nomograms (5). When new generations of faster lasers, improved
ablation algorithms, and nomograms have emerged, it allowed development of a new TPRK non
touch: all-surface ablation technique which allows ablation the corneal epithelium and stroma
in a single-step with one ablation profile. This aspheric profile is calculated according to
data from the literature estimating that the normal corneal epithelial thickness is 55 μm
centrally and 65 peripherally at 4 mm radially from the center (6). A number of recent
studies demonstrated that this single-step TPRK is a relatively new procedure with many
advantages such as, reduced surgical time, minimizing the size of epithelial defect to that
required for stromal ablation, no alcohol use avoiding potential toxicity to the limbal
cells, less post-operative pain and corneal haze with rapid healing time and faster visual
recovery (7).Thus, there is a need for an updated comparative evaluation based on a larger
number of eyes. The aim of our study is to compare 6-months un-corrected distant visual
acuity (UDVA) and best corrected distant visual acuity (BCDVA) means, refractive results,
safety, and efficacy of single-step TPRK with alcohol-assisted PRK (AAPRK) as primary
outcomes and comparison of surgical time, pain scores, and haze levels, complete epithelial
healing time, as secondary outcomes among the two procedures when used to correct mild to
moderate myopia and myopic astigmatism.
Subjects and methods This study is a prospective, consecutive, nonrandomized case-control
study that includes eyes that underwent either single-step TPRK or AAPRK between February
2017 and April 2018, at the Security Forces Hospital, Ophthalmology department, Riyadh,
Kingdom of Saudi Arabia. The study was approved by the local ethical board committee. Before
the surgical procedure, each patient was adequately informed about the study as well as the
risks and benefits of the surgery, and signed informed consent in accordance with the
Declaration of Helsinki.
A total of 200 eyes of 100 consecutive patients were included; One hundred eyes underwent
TPRK (study group) and 100 eyes underwent AAPRK (control group). The study design choice of
the procedure was fixed for each patient: the right eye underwent TPRK and the contra-lateral
left eye AAPRK. Patients demographics and preoperative variables are demonstrated in Table
(1). There are no significant differences in pre-operative variables of patients in the TPRK
and AAPRK groups except the patients' genders. The percentage of females is 77% and males
23%. Patients who attended all visits, without any missing data, were included in the
statistical analysis.
Preoperative Examination The preoperative examination included UDVA, BCDVA, manifest and
cycloplegic refraction, slit lamp biomicroscopy, tonometry, Pentacam camera (OCULUS- Netzteil
Art., pentacam HR, Germany), tomography (Sirius, SCHWIND eye-tech-solutions GmbH,
Kleinostheim, Germany), and dilated fundus examination using binocular ophthalmoscopy.
Contact lenses use and medical history, including any systemic diseases, were recorded.
Surgical Technique All surgeries were performed with 6th-generation Amaris excimer LASER 193,
version 750 S (Schwind eye-tech-solutions GmbH& Co.KG, Mainparkstrasse, Kleinostheim,
Germany). Ablations were based on aberration-free algorithms calculated using ORK-CAM
software with beam size 0.54 mm full width and high-speed eye tracking. Treatments were
performed by 2 surgeons (BA & ESH ) using an identical surgical protocol. The treatments were
mostly aimed at emmetropia. Before the surgery, tetracaine hydrochloride 0.5% ophthalmic
solution (Bausch & Lomb, Minims) and moxifloxacin 0.5% (Vigamox, Alcon Co.) drops were
instilled 3 times within a 5-minutes interval. The eyelids were prepared with antiseptic
Chlorohexidine Gluconate 0.05% solution (Saudi Medical Solution Company) and opened using a
wire lid speculum. In the AAPRK group, the cornea was exposed to a 20% ethyl alcohol solution
for 25 seconds with the use of a well. Subsequently, a superficial cut of the epithelium was
made with either an 8.5 or 9.5 mm diameter trephine. The epithelium was mechanically debrided
with the well or with a blunt spatula, then LASER treatment with the same machine was
initiated. In the TPRK group, where aspheric aberration-free TPRK ablation algorithm was used
(Schwind eye-tech-solutions), the epithelium was removed during laser ablation only from the
area of the total ablation zone. In both groups and in all cases, immediately after
treatment, the eye was washed with a balanced salt solution (BSS) for 20 seconds. Then, to
fight against post-operative corneal haze, mitomycin C 0.02% (MMC) was applied for 30 seconds
followed by copious irrigation of the eye with BSS. Intra-operative complications were not
noted and surgical time starting from eye lid speculum insertion to the time of its removal
at the end of the procedure were recorded. After the surgery, a bandage contact lens was
applied (BIOMEDICS Evolution CL ocufilcon D 45%, water 55%) for 7 days. The postoperative
regimen included tobradex eye drops 0.3% (Tobramycin 0.3% - dexamethazone 0.1% sterile eye
drops, Alcon Co.) with tapering dose for 1 month starting with QID/ 1 week, TID/ 1 week, BID/
1 week and once a day/1 week, moxifloxacin drops 0.5% (Vigamox, Alcon Co.) for 2 weeks, and
sodium hyaluronate 0.2% (Hyfresh eye drops, Jamjoom Pharma Co.) drop / 2 hours and a gradual
decreasing of the frequency for 3 months. Pain killer oral medication tablet/ 6 hours was
used in the first post-operative days if needed.
Postoperative Examinations Patients were instructed to visit the clinic for postoperative
examinations and follow up after 1 day, 1 week, 1 month, 3 months and 6 months. Examinations
at 1 day, 1 week, 1 month, 3 months, and 6 months included UDVA ,but the BCDVA and manifest
refraction were measured at 1, 3, and 6 months. Slit lamp biomicroscopy was done in each
visit. Corneal haze grading was evaluated according to Fantes et al., 1990 proposal (0 = no
haze; 0.5 = trace haze on oblique illumination; 1 = corneal cloudiness not interfering with
the visibility of fine iris details; 2 = mild effacement of fine iris details; 3 and 4 =
details of the lens and iris not discernible). Healing time in which complete
re-epithelialisation occurred in both eyes were recorded. In post-operative day 1, day 3 and
week 1, We used a discrete, 11-category numeric pain scale (NPS, 0 = no pain and 10 = the
worst possible pain) to evaluate pain score in each eye and patients response were recorded
at early postoperative period. Six months post-operatively, patients were asked about the
overall satisfaction with each procedure as high, moderate, low, and not satisfied, and
whether they would decide to have the surgery again (yes, no) were recorded.
Statistical Analysis Patients' data were entered in Microsoft Excel, copied and analyzed
using Sigma Plot-Scientific Data Program for the 2 groups, Paired student's t-test was used
for the UDVA & BCDVA means in decimal values and for MRSE means. Mann-Whitney test was used
for pain scores, haze levels, and healing time. For all tests, a (P value < 0.05) was
considered statistically significant. A Graph Pad Prism 5 program was used for graphs
constructions.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04923841 -
Myopia Control Using Bright Light Therapy, Myopic Defocus and Atropine
|
N/A | |
Active, not recruiting |
NCT04080128 -
Examination of Myopia Progression and Soft Bifocal Contact Lens Myopia Control
|
N/A | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Completed |
NCT04604405 -
Effects of 650nm Low Energy Light on Human Retina and Choroid Microcirculation
|
N/A | |
Recruiting |
NCT05594719 -
The Effect of Sun-like Spectrum With Different Spectrum Composition on Retinal Blood Flow
|
N/A | |
Completed |
NCT05594732 -
The Effects of Different Outdoor Light Exposure Modes on Retinal Blood Flow
|
N/A | |
Completed |
NCT04492397 -
Comparing The Performance Of Two Different Daily Disposable Lenses (MIKI)
|
N/A | |
Completed |
NCT04536571 -
Vision Stability and Preference for Soft Toric vs. Soft Spherical Contact Lenses
|
N/A | |
Completed |
NCT06046209 -
Comparing a Monthly Replacement Lens Versus a Daily Disposable Lens
|
N/A | |
Recruiting |
NCT06344572 -
Pivotal Study of SAT-001 in Treatment of Pediatric Patient With Myopia
|
Phase 3 | |
Recruiting |
NCT05611294 -
Contralateral Study of Topography Guided LASIK Versus Small Incision Lenticule Extraction
|
N/A | |
Completed |
NCT05656885 -
Clinical Evaluation of Two Frequent Replacement Soft Spherical Contact Lenses
|
N/A | |
Active, not recruiting |
NCT05534022 -
Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression.
|
N/A | |
Completed |
NCT03934788 -
the Clinical Performance of the Oxysoft Daily Disposable Silicone Hydrogel Soft Contact Lens
|
N/A | |
Completed |
NCT03701516 -
Clinical Evaluation of Etafilcon A Contact Lenses Using a Novel Molding Process 2
|
N/A | |
Completed |
NCT05538754 -
Post-Market Evaluation of the EVO ICL
|
N/A | |
Completed |
NCT03139201 -
Clinical Performance of the OxyAqua Daily Disposable Silicone Hydrogel Soft Contact Lens
|
N/A | |
Completed |
NCT02555722 -
Evaluation of the CooperVision, Inc. Fanfilcon A and Enfilcon A Daily Wear Contact Lenses When Used for Frequent Replacement for up to One (1) Month of Daily Wear
|
N/A | |
Not yet recruiting |
NCT06009458 -
Acuity 200™ (Fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear
|
N/A | |
Recruiting |
NCT05548478 -
Corneal Endothelial Cell Injury Induced by Mitomycin-C
|
N/A |